Non-Small-Cell Lung study: PF-08046033
Official title Phase 1 Study of PF-08046033 in Advanced Solid Tumors
ClinicalTrials.gov ID: NCT07519655
What this study is testing
What is PF-08046033?
This is an investigational medicine being studied as a potential treatment for non-small cell lung cancer.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn how safe the drug is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping treat cancer.
- Who it's for
- Adults with advanced non‑small‑cell lung cancer, esophageal squamous cell cancer, or melanoma that cannot be removed by surgery or has spread.
- What's involved
- Participants receive the drug in regular treatment cycles and are closely monitored for side effects and cancer response through tests and visits.
- Time commitment
- The study lasts several months, with multiple clinic visits for drug administration and monitoring.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have histologically-confirmed metastatic or unresectable locally advanced NSCLC, ESCC, or cutaneous melanoma.
- Participants must have disease that has progressed on or be unable to tolerate standard treatments (Part 1) or 1-2 prior systemic therapies (Part 2).
- Participants must have measurable disease.
- Eastern Cooperative Oncology Group (ECOG) performance status is 0-1.
You likely can't join if
- Participants with known clinically active central nervous system (CNS) metastases.
- Participants with pre-existing neuropathy ≥Grade 2 per NCI CTCAE v 5.0.
- Uncontrolled diabetes mellitus with hemoglobin (Hgb) A1C ≥10.0%.
- Untreated clinically significant thromboembolic disease.
- Previous exposure to GPNMB-targeted therapy.
- Known or suspected hypersensitivity to any component or excipient contained in the drug formulation of study intervention.
The study team makes the final eligibility decision.
Where it is enrolling
- Denver, Colorado, United States
- New Haven, Connecticut, United States
- Trumbull, Connecticut, United States
- Nashville, Tennessee, United States
- Fairfax, Virginia, United States
- Toulouse, France
- Villejuif, France
- Rio Piedras, Puerto Rico
- Seoul, Seoul-teukbyeolsi [seoul], South Korea
- Barcelona, Barcelona [barcelona], Spain
- Madrid, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Denver, Colorado, United States; New Haven, Connecticut, United States; Trumbull, Connecticut, United States; Nashville, Tennessee, United States; Fairfax, Virginia, United States; Toulouse, France and 5 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.